Lack of referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: A nationwide study based on 240,134 consultations and 134,652 genetic tests

Breast Cancer Research and Treatment

Volumn 141, Issue 1, 2013, Pages 135-144

  Pujol, P ^a,b   Lyonnet, D Stoppa ^c   Frebourg, T ^d   Blin, J ^e   Picot, M C ^a   Lasset, C ^f   Dugast, C ^g   Berthet, P ^h   De Paillerets, B Bressac ⁱ   Sobol, H ^j   Grandjouan, S ^k   Soubrier, F ^l   Buecher, B ^c,m   Guimbaud, R ⁿ   Lidereau, R ^c   Jonveaux, P ^o   Houdayer, C ^c   Giraud, S ^p   Olschwang, S ^q   Nogue, E ^a   Galibert, V ^a   Bara, C ^e   Nowak, F ^e   Khayat, D ^e,l   Nogues, C ^c   more..

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

^c INSTITUT CURIE   (France)

^d ROUEN UNIVERSITY HOSPITAL   (France)

^e INSTITUT NATIONAL DU CANCER   (France)

^f CENTRE LÉON BÉRARD   (France)

^g CENTRE EUGÈNE MARQUIS   (France)

^h CENTRE FRANÇOIS BACLESSE   (France)

ⁱ INSTITUT GUSTAVE ROUSSY   (France)

^j INSTITUT PAOLI CALMETTES   (France)

^k Institut Cochin   (France)

^l PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^m HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

ⁿ INSTITUT CLAUDIUS REGAUD   (France)

^o UNIVERSITY HOSPITAL OF NANCY   (France)

^p EDOUARD HERRIOT HOSPITAL   (France)

^q TIMONE HOSPITAL   (France)

more..

Author keywords

BRCA1; BRCA2; Cancer genetics; Lynch syndrome

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ARTICLE; BREAST CANCER; CANCER GENETICS; CANCER SUSCEPTIBILITY; CONSULTATION; FAMILIAL CANCER; FEMALE; FRANCE; GENE; GENE MUTATION; GENETIC ANALYSIS; GENETIC COUNSELING; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MMR GENE; OVARY CANCER; PATIENT REFERRAL; POPULATION RESEARCH; PRIORITY JOURNAL;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BREAST NEOPLASMS; CANCER CARE FACILITIES; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA MISMATCH REPAIR; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; FAMILY HEALTH; FEMALE; FRANCE; GENES, BRCA1; GENES, BRCA2; GENETIC COUNSELING; GENETIC TESTING; HETEROZYGOTE DETECTION; HUMANS; LABORATORIES; MALE; MUTATION; MUTS HOMOLOG 2 PROTEIN; NEOPLASTIC SYNDROMES, HEREDITARY; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; REFERRAL AND CONSULTATION;

EID: 84884284192     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2669-9     Document Type: Article

References (44)

1. Robson M, Offit K (2007) Clinical practice. Management of an inherited predisposition to breast cancer. N Engl J Med 357:154-162
2. Narod SA (2010) BRCA mutations in the management of breast cancer: the state of the art. Nat Rev Clin Oncol 7:702-707
3. Lynch HT, Lynch PM, Lanspa SJ et al (2009) Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet 76:1-18
4. Järvinen HJ, Renkonen-Sinisalo L, Aktán-Collán K et al (2009) Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol 27:4793-4797
5. Rebbeck TR, Friebel T, Lynch HT et al (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 22:1055-1062
6. Domchek SM, Rebbeck TR (2007) Prophylactic oophorectomy in women at increased cancer risk. Curr Opin Obstet Gynecol 19:27-30
7. Lindor NM, Petersen GM, Hadley DW et al (2006) Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 27(296):1507-1517
8. National Comprehensive Cancer Network (NCCN) (2012) The NCCN guidelines for detection, prevention and risk reduction. http://www.nccn.org. Accessed 20 Aug 2013
9. Ropka ME, Wenzel J, Phillips EK et al (2006) Uptake rates for breast cancer genetic testing: a systematic review. Cancer Epidemiol Biomarkers Prev 15:840-855
10. Cheung EL, Olson AD, Yu TM et al (2010) Communication of BRCA results and family testing in 1,103 high-risk women. Cancer Epidemiol Biomarkers Prev 19:2211-2219
11. Patenaude AF, Dorval M, DiGianni LS et al (2006) Sharing BRCA1/2 test results with first-degree relatives: factors predicting who women tell. J Clin Oncol 24:700-706
12. Trivers KF, Baldwin LM, Miller JW et al (2011) Reported referral for genetic counseling or BRCA 1/2 testing among United States physicians: a vignette-based study. Cancer 117:5334-5343. doi: 10.1002/cncr.26166
13. Burke W, Culver J, Pinsky L et al (2009) Genetic assessment of breast cancer risk in primary care practice. Am J Med Genet A 149A:349-356
14. Meyer LA, Anderson ME, Lacour RA et al (2010) Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities. Obstet Gynecol 115:945-952
15. Koil CE, Everett JN, Hoechstetter L et al (2003) Differences in physician referral practices and attitudes regarding hereditary breast cancer by clinical practice location. Genet Med 5:364-369
16. Bellcross CA, Kolor K, Goddard KA, Coates RJ, Reyes M, Khoury MJ (2003) Awareness and utilization of BRCA1/2 testing among U.S. primary care physicians. Am J Prev Med 40:61-66
17. Foretova L, Petrakova K, Palacova M et al (2010) Genetic testing and prevention of hereditary cancer at the MMCI-over 10 years of experience. Klin Onkol 23:388-400
18. Hall MJ, Reid JE, Burbridge LA et al (2009) BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer 115:2222-2233
19. INSEE, Government of France (2011) Population totale par sexe et âge au 1er janvier 2011, France métropolitaine. http://www.insee.fr. Accessed 8 Feb 2011
20. Eisinger F, Bressac B, Castaigne D et al (2004) Identification and management of hereditary predisposition to cancer of the breast and the ovary (update 2004). Bull Cancer 91:219-237 (in French)
21. Olschwang S, Bonaïti C, Feingold J et al (2004) Identification and management of HNPCC syndrome (hereditary non polyposis colon cancer), hereditary predisposition to colorectal and endometrial adenocarcinomas. Bull Cancer 91:303-315 (in French)
22. Cohen M, Jacquemier J, Maestro C et al (2011) Recommandations pour la Pratique Clinique: Femmes à risque. Oncologie 13(10-11):618-645 (in French)
23. Bonaïti-Pellié C, Andrieu N, Arveux P et al (2009) Cancer genetics: estimation of the needs of the population in France for the next ten years. Bull Cancer 96:875-900
24. 2 tests. Biometrics 10:417-451
25. Armitage P (1955) Tests for linear trends in proportions and frequencies. Biometrics 11:75-386
26. Petrucelli N, Daly MB, Feldman GL (2010) Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genet Med 12:245-259
27. Antoniou A, Pharoah PD, Narod S et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:117-130
28. Mitchell RJ, Farrington SM, Dunlop MG et al (2002) Mismatch repair genes hMLH1 and hMSH2 and colorectal cancer: a HuGE review. Am J Epidemiol 156:885-902
29. Bonaïti-Pellié C, Eisinger F, Feingold J et al (2005) Hereditary predispositions to colorectal cancer. Gastroenterol Clin Biol 29:701-710
30. Salovaara R, Loukola A, Kristo P et al (2000) Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol 18(2193):2200; Erratum in: J Clin Oncol 2000 18:3456
31. Foo W, Young JM, Solomon MJ et al (2009) Family history? The forgotten question in high-risk colorectal cancer patients. Colorectal Dis 11:450-455
32. Singh H, Schiesser R, Anand G et al (2010) Underdiagnosis of Lynch syndrome involves more than family history criteria. Clin Gastroenterol Hepatol 8:523-529
33. Van Dijk DA, Oostindiër MJ, Kloosterman-Boele WM, Hereditary Tumor Study Group of the Comprehensive Cancer Centre West et al (2007) Family history is neglected in the work- up of patients with colorectal cancer: a quality assessment using cancer registry data. Fam Cancer 6:131-134
34. Easton DF, Bishop DT, Ford D et al (1993) Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The breast cancer linkage consortium. Am J Hum Genet 52:678-701
35. Shattuck-Eidens D, Oliphant A, McClure M et al (1997) BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 278:1242-1250
36. Kwong A, Ng EK, Wong CL et al (2012) Identification of BRCA1/2 founder mutations in Southern Chinese breast cancer patients using gene sequencing and high resolution DNA melting analysis. PLoS ONE 7:e43994
37. Fackenthal JD, Olopade OI (2007) Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 7:937-948
38. Walsh T, Casadei S, Coats KH et al (2006) Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295:1379-1388
39. Turnbull C, Ahmed S, Morrison J et al (2010) Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet 42:504-507
40. Metcalfe KA, Finch A, Poll A et al (2009) Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation. Br J Cancer 100:421-425
41. Julian-Reynier C, Eisinger F, Evans G et al (2000) Variation in prophylactic surgery decisions. Lancet 356:1687
42. Lapointe J, Côté C, Bouchard K et al (2012) Life Events may contribute to family communication about cancer risk following BRCA1/2 testing. J Genet Couns. doi: 10.1007/s10897-012-9531-9
43. Fischer C, Engel C, Sutter C, German Consortium for Hereditary Breast and Ovarian Cancer et al (2012) BRCA1/2 testing: uptake, phenocopies, and strategies to improve detection rates in initially negative families. Clin Genet 82:478-483. doi: 10.1111/j.1399-0004.2011.01788.x
44. Evans DG, Binchy A, Shenton A et al (2009) Comparison of proactive and usual approaches to offering predictive testing for BRCA1/2 mutations in unaffected relatives. Clin Genet 75:24-32